您的位置: 首页 > 农业专利 > 详情页

Pyrrolopyrimidine compounds as CDK inhibitors
专利权人:
Novartis AG;Astex Therapeutics Ltd.
发明人:
Besong, Gilbert,Brain, Christopher Thomas,Brooks, Clinton A.,Congreve, Miles Stuart,Dagostin, Claudio,He, Guo,Hou, Ying,Howard, Steven,Li, Yue,Lu, Yipin,Mortenson, Paul,Smith, Troy,Sung, Moo,Woodhead,
申请号:
AU2009284098
公开号:
AU2009284098B2
申请日:
2009.08.20
申请国别(地区):
AU
年份:
2012
代理人:
摘要:
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充